.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, people with metastatic stomach growths that got biomarker-matched therapies based upon spreading cyst DNA profiling revealed a better clinical perk than those obtaining unequaled treatment.